Image

Global Active Pharmaceutical Ingredient (API) Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Active Pharmaceutical Ingredient (API) Market, By Molecule (Small Molecule, Large Molecule), Type (Innovative Active Pharmaceutical Ingredients, Generic Innovative Active Pharmaceutical Ingredients), Type of Manufacturer (Captive API Manufacturer, Merchant API Manufacturer), Synthesis (Synthetic Active Pharmaceutical Ingredients and Biotech Active Pharmaceutical Ingredients), Chemical Synthesis (Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, Tamoxifen, Others), Type of Drug (Prescription Drugs, Over-the-Counter), Usage (Clinical, Research), Potency (Low-to-Moderate Potency Active Pharmaceutical Ingredients, Potent-to-Highly Potent Active Pharmaceutical Ingredient), Therapeutic Application (Cardiology, CNS & Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Other Therapeutic Application), Industry Trends and Forecast to 2029

 

Active Pharmaceutical Ingredient (API) Market

Active Pharmaceutical Ingredient (API) Market Analysis and Insights

The active pharmaceutical ingredient (API) is a drug's active component. In layman's terms, API is a component of any drug that produces the desired effects. Drugs are typically made up of several components. The primary ingredient is the API. Excipients are other ingredients that are required to be biologically innocuous and often form a changeable fraction of the drug product. Formulation refers to the process of optimising and composing the mixture of ingredients used in the medicine. Some drugs contain multiple active APIs in order to treat multiple symptoms or act in complex ways. Local pharmaceutical companies have done the majority of API production.

Data Bridge Market Research analyses that the active pharmaceutical ingredient (API) market was valued at USD 300,722.26 billion in 2021 and is expected to reach at value of USD 540335.81 billion by 2029 at a CAGR of 7.6% during the forecast period of 2022 to 2029. The rising prevalence of various chronic diseases and an ageing population are the major drivers driving the active pharmaceutical ingredients (API) market during the forecast period. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Active Pharmaceutical Ingredient (API) Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Molecule (Small Molecule, Large Molecule), Type (Innovative Active Pharmaceutical Ingredients, Generic Innovative Active Pharmaceutical Ingredients), Type of Manufacturer (Captive API Manufacturer, Merchant API Manufacturer), Synthesis (Synthetic Active Pharmaceutical Ingredients and Biotech Active Pharmaceutical Ingredients), Chemical Synthesis (Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, Tamoxifen, Others), Type of Drug (Prescription Drugs, Over-the-Counter), Usage (Clinical, Research), Potency (Low-to-Moderate Potency Active Pharmaceutical Ingredients, Potent-to-Highly Potent Active Pharmaceutical Ingredient), Therapeutic Application (Cardiology, CNS & Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Other Therapeutic Application)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Novartis AG (Switzerland), Sanofi (France). Pfizer Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Bausch Health Companies Inc. (Canada), UCB S.A. (Belgium), Sunovion Pharmaceuticals Inc. (U.S.), GW Pharmaceuticals plc. (U.k.), AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), H. Lundbeck A/S (Denmark), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Dainippon Pharma Co., Ltd. (Japan), Cadila Pharmaceuticals (India)

Opportunities

  • Rising research and development activities
  • Rapid technological advancements in healthcare technologies

Active Pharmaceutical Ingredient (API) Market Dynamics

Drivers

  • Rapid technological advancements

Increased technological advancements will improve market players' capabilities and manufacturing skills, allowing them to provide APIs in bulk and meet consumer demand, potentially driving the growth of the global active pharmaceutical ingredients (API) market.

  • Increasing investment for healthcare infrastructure

Rising investment in API research and development will expand the global active pharmaceutical ingredients (API) market's growth opportunities.

  • High prevalence of chronic diseases

The rising prevalence of chronic diseases is expected to increase drug demand, fuelling the growth of the active pharmaceutical ingredients market in the near future. Furthermore, new drug and biological product launches, acquisitions, collaborations, and regional expansions are some of the strategic initiatives to maintain market stability.

Furthermore, advancement in medical technology, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the active pharmaceutical ingredient (API) market. Additionally, high disposable income, rising number of cases of seizures and changing lifestyle will expand the active pharmaceutical ingredient (API) market. 

Opportunities

  • Rise in the investment for R&D by public and private organizations

Moreover, the rise in the research and development activities and increasing investments by government and private organization will boost new opportunities for the market's growth rate.

Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the active pharmaceutical ingredient (API) market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate active pharmaceutical ingredient (API) market in future.

Restraints/Challenges

However, the availability of substandard and counterfeit drugs is stifling demand in the global active pharmaceutical ingredients (API) market. Disruption in the API supply chain during COVID-19 poses a challenge to healthcare providers and may pose a threat to the global active pharmaceutical ingredients (API) market. The lack of cure for this neurological condition and less awareness about genetic and rare diseases will further challenge the market in the forecast period mentioned above.

This active pharmaceutical ingredient (API) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on active pharmaceutical ingredient (API) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Active pharmaceutical ingredient (API) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Active Pharmaceutical Ingredient (API) Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.

Recent Development

  • Novasep, a provider of services and technologies to the life sciences industry, invested approximately EUR 6 million in its Chasse-sur-Rhône, France site in December 2021 to upgrade its capabilities in areas such as oncology, central nervous system (CNS), and infectious diseases.
  • Teva Pharmaceutical and MEDinCell were approved by the US Food and Drug Administration (FDA) in August 2021 for a New Drug Application for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use). The medication is being used to treat schizophrenia.
  • Pfizer Inc. announced a multi-year agreement with Gilead Sciences Inc. in August 2020 to manufacture and supply Gilead's investigational antiviral remdesivir, assisting efforts to scale up supply of the investigational treatment for COVID-19.).

Global Active Pharmaceutical Ingredient (API) Market Scope

The active pharmaceutical ingredient (API) market is segmented on the basis of molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Molecule

  • Small molecule
  • Large molecule

Type

  • Innovative Active Pharmaceutical Ingredients
  • Generic Active Pharmaceutical Ingredients

Type of manufacturer

  • Captive API Manufacturer
  • Merchant API Manufacturer

Synthesis

  • Synthetic Active Pharmaceutical Ingredients
  • Biotech Active Pharmaceutical Ingredients

Indications

  • Acetaminophen
  • Artemisinin
  • Saxagliptin
  • Sodium Chloride
  • Ibuprofen Losartan Potassium
  • Enoxaparin Sodium
  • Rufinamide
  • Naproxen
  • Tamoxifen
  • Others

Type of drugs

  • prescription drugs
  • over the counter drugs

Usage

  • clinical
  • research

Potency

  • low-to-moderate potency active pharmaceutical ingredients
  • potent-to-highly potent active pharmaceutical ingredient

Therapeutic application

  • cardiology
  • CNS & neurology
  • Oncology
  • Orthopaedic
  • Endocrinology
  • Pulmonology
  • Gastroenterology
  • Nephrology
  • Ophthalmology
  • other therapeutic application

Active Pharmaceutical Ingredient (API) Market Regional Analysis/Insights

The active pharmaceutical ingredient (API) market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, indications, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the active pharmaceutical ingredient (API) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Due to rising healthcare expenditures and well-established healthcare infrastructure, the United States dominates the North America active pharmaceutical ingredients (API) market. The small molecule segment in North America is expected to grow at the fastest rate during the forecast period of 2021 to 2028. China is leading the growth of the Asia-Pacific active pharmaceutical ingredients (API) market, and the small molecule segment is dominating in the country as active pharmaceutical ingredients (API) become more affordable. Due to increased consumption demand for active pharmaceutical ingredients, Germany's small molecule segment dominates the Europe active pharmaceutical ingredients (API) market.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Active Pharmaceutical Ingredient (API) Market Share Analysis

The active pharmaceutical ingredient (API) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to active pharmaceutical ingredient (API) market.

Some of the major players operating in the active pharmaceutical ingredient (API) market are

  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • Johnson & Johnson Private Limited (U.S.)
  • Abbott (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Bausch Health Companies Inc. (Canada)
  • UCB S.A. (Belgium)
  • Sunovion Pharmaceuticals Inc. (U.S.)
  • GW Pharmaceuticals plc. (U.K.)
  • AstraZeneca (U.K.)
  • GlaxoSmithKline plc (U.K.)
  • H. Lundbeck A/S (Denmark)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Cadila Pharmaceuticals (India)

Research Methodology

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Active Pharmaceutical Ingredient (API) Market value is expected USD 540335.81 billion by 2029.
The Active Pharmaceutical Ingredient (API) Market is to grow at a CAGR of 7.6% during the forecast by 2029.
On the basis of application, the Active Pharmaceutical Ingredient (API) Market is segmented into Cardiology, CNS & Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Other Therapeutic Application.
The major players operating in the Active Pharmaceutical Ingredient (API) Market are Novartis AG (Switzerland), Sanofi (France). Pfizer Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Bausch Health Companies Inc. (Canada), UCB S.A. (Belgium), Sunovion Pharmaceuticals Inc. (U.S.), GW Pharmaceuticals plc. (U.k.), AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), H. Lundbeck A/S (Denmark), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Dainippon Pharma Co., Ltd. (Japan), Cadila Pharmaceuticals (India).